BR112015020911A2 - antibody, use of a combination and treatment method - Google Patents

antibody, use of a combination and treatment method

Info

Publication number
BR112015020911A2
BR112015020911A2 BR112015020911A BR112015020911A BR112015020911A2 BR 112015020911 A2 BR112015020911 A2 BR 112015020911A2 BR 112015020911 A BR112015020911 A BR 112015020911A BR 112015020911 A BR112015020911 A BR 112015020911A BR 112015020911 A2 BR112015020911 A2 BR 112015020911A2
Authority
BR
Brazil
Prior art keywords
combination
antibody
treatment method
treatment
abstract
Prior art date
Application number
BR112015020911A
Other languages
Portuguese (pt)
Inventor
Ries Carola
Ruettinger Dominik
Wartha Katharina
Hoves Sabine
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015020911A2 publication Critical patent/BR112015020911A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “anticorpo, uso de uma combinação e método de tratamento” a presente invenção refere-se à terapia de combinação de anticorpos contra csf-1r humano com agonista de tlr9.abstract "antibody, use of a combination and method of treatment" the present invention relates to the combination therapy of antibodies against human csf-1r with tlr9 agonist.

BR112015020911A 2013-04-22 2014-04-17 antibody, use of a combination and treatment method BR112015020911A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13164695 2013-04-22
PCT/EP2014/057909 WO2014173814A1 (en) 2013-04-22 2014-04-17 Combination therapy of antibodies against human csf-1r and tlr9 agonist

Publications (1)

Publication Number Publication Date
BR112015020911A2 true BR112015020911A2 (en) 2017-10-10

Family

ID=48141840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020911A BR112015020911A2 (en) 2013-04-22 2014-04-17 antibody, use of a combination and treatment method

Country Status (13)

Country Link
US (2) US9192667B2 (en)
EP (1) EP2989125B1 (en)
JP (1) JP6506254B2 (en)
KR (1) KR20150132580A (en)
CN (1) CN104995213A (en)
AR (1) AR095882A1 (en)
BR (1) BR112015020911A2 (en)
CA (1) CA2898591A1 (en)
HK (1) HK1211305A1 (en)
MX (1) MX2015014500A (en)
RU (1) RU2015149929A (en)
TW (1) TW201444873A (en)
WO (1) WO2014173814A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557454T3 (en) 2009-12-10 2016-01-26 F. Hoffmann-La Roche Ag Antibodies that bind to the extracellular domain 4 of human CSF1R and its use
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
MX336682B (en) 2010-03-05 2016-01-27 Hoffmann La Roche Antibodies against human csf-1r and uses thereof.
MX356337B (en) 2011-12-15 2018-05-23 Hoffmann La Roche Antibodies against human csf-1r and uses thereof.
AR095882A1 (en) 2013-04-22 2015-11-18 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AR097584A1 (en) 2013-09-12 2016-03-23 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
WO2015048006A2 (en) 2013-09-24 2015-04-02 3B Product Development, Llc Protective cover and retractable lanyard
EP3508198A1 (en) 2014-06-04 2019-07-10 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3682889B1 (en) * 2015-08-06 2023-02-01 Regents of the University of Minnesota Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
EP3383173B1 (en) * 2015-11-30 2020-11-25 H. Hoffnabb-La Roche Ag Generation of human macrophages in immunodeficient mice
KR102531889B1 (en) 2016-06-20 2023-05-17 키맵 리미티드 Anti-PD-L1 and IL-2 cytokines
CN109843327B (en) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 Antibody adjuvant conjugates
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
BR112019008335A2 (en) * 2016-10-28 2020-01-28 Toray Industries conjugate of an antibody, pharmaceutical composition and method for the treatment and / or prevention of cancer
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
CN108728444A (en) 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 Immunoregulation polynucleotide and its application
AU2018256406A1 (en) 2017-04-19 2019-10-17 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
US20200377571A1 (en) 2017-12-08 2020-12-03 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
BR112020017778A2 (en) * 2018-03-02 2021-01-05 Elicio Therapeutics, Inc. CPG AMPHIPHILS AND USES THEREOF
CN109053888B (en) * 2018-07-18 2020-06-19 博奥信生物技术（南京）有限公司 Anti-human CSF-1R monoclonal antibody and application thereof
CN109053886B (en) * 2018-07-18 2020-07-28 博奥信生物技术（南京）有限公司 Anti-human CSF-1R monoclonal antibody and application
AU2019346645A1 (en) 2018-09-27 2021-04-29 Marengo Therapeutics, Inc. CSF1R/CCR2 multispecific antibodies
CN109364252B (en) * 2018-11-21 2021-09-28 南京大学 Application of inhibiting IFN-I to ARG1 induction pathway in preparation of anti-tumor pharmaceutical composition
WO2020124039A1 (en) * 2018-12-13 2020-06-18 Development Center For Biotechnology Anti-human csf-1r antibody and uses thereof
KR20210134353A (en) 2019-02-28 2021-11-09 에스큐지 바이오테크놀로지스 컴퍼니 Delivery of Biomolecules to PBMCs to Modify the Immune Response
KR20220004634A (en) 2019-03-15 2022-01-11 볼트 바이오테라퓨틱스 인코퍼레이티드 Immunoconjugates targeting HER2
AU2020256136A1 (en) * 2019-03-29 2021-12-02 Kolon Tissuegene, Inc. Cartilage regeneration using chondrocyte and TGF-β

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0668914B1 (en) 1992-06-09 2000-08-16 Chiron Corporation Crystallization of m-csf
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE69833755T2 (en) 1997-05-21 2006-12-28 Biovation Ltd. METHOD FOR PRODUCING NON-IMMUNOGENOUS PROTEINS
WO1999017798A1 (en) 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
DE19935756A1 (en) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Covalently closed nucleic acid molecule for immune stimulation
ES2197885T3 (en) 1999-10-28 2004-01-16 Hofbauer, Reinhold USE OF CSF-1 INHIBITORS.
PT1242438E (en) 1999-12-29 2007-02-28 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
EP1412390A2 (en) 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
EP2287192B1 (en) 2002-11-15 2015-08-26 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
KR101107818B1 (en) 2003-10-30 2012-01-31 콜레이 파마시티컬 그룹, 인코포레이티드 C-class oligonucleotide analogs with enhanced immunostimulatory potency
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
DK2489364T3 (en) 2003-11-06 2015-03-02 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies
US20070264277A1 (en) 2004-07-22 2007-11-15 Dirk Behrens Compositions and Methods of Use for Mgd-Csf in Disease Treatment
WO2006096489A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
CN101287742B (en) 2005-10-12 2016-01-06 艾德拉药物股份有限公司 Based on immunomodulatory oligonucleotide (IRO) compound of variation response modulation Toll-like receptor
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
JP2009518441A (en) 2005-12-09 2009-05-07 シアトル ジェネティクス，インコーポレーテッド How to use a CD40 binder
JP2009520502A (en) 2005-12-20 2009-05-28 イデラ ファーマシューティカルズ インコーポレイテッド Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications
JPWO2007119815A1 (en) 2006-04-14 2009-08-27 協和発酵キリン株式会社 Toll-like receptor 9 agonist
CN101610671A (en) 2006-12-12 2009-12-23 艾德拉药物股份有限公司 Synthetic TLR9 activator
AU2008222523A1 (en) 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
CN101878311A (en) 2007-08-01 2010-11-03 艾德拉药物股份有限公司 Novel synthetic agonists of TLR9
SI2188313T1 (en) 2007-08-21 2018-04-30 Amgen, Inc. Human c-fms antigen binding proteins
CN101970496B (en) 2008-03-14 2014-04-16 特朗斯吉有限公司 Antibody against the csf-1 r
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
EP2271673B1 (en) 2008-03-26 2016-02-24 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
CN114835812A (en) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 anti-PD-L1 antibodies and their use for enhancing T cell function
AU2010208250A1 (en) 2009-01-30 2011-08-04 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR 9
CA2992770A1 (en) 2009-11-24 2011-06-03 Medimmune Limited Targeted binding agents against b7-h1
ES2557454T3 (en) 2009-12-10 2016-01-26 F. Hoffmann-La Roche Ag Antibodies that bind to the extracellular domain 4 of human CSF1R and its use
MX336682B (en) 2010-03-05 2016-01-27 Hoffmann La Roche Antibodies against human csf-1r and uses thereof.
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
AR080698A1 (en) 2010-04-01 2012-05-02 Imclone Llc ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
CN106977603B (en) 2010-05-04 2020-11-27 戊瑞治疗有限公司 Antibodies that bind CSF1R
JP5798404B2 (en) 2010-08-31 2015-10-21 日東電工株式会社 Adhesive tape for electrode plate protection
CA2817891C (en) * 2010-11-19 2021-10-12 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
FR2975600B1 (en) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris AGENTS FOR THE TREATMENT OF TUMORS
CA2841013C (en) 2011-07-18 2020-04-21 Morphosys Ag Use of c-fms antagonists
MX355830B (en) 2011-10-21 2018-05-02 Transgene Sa Modulation of macrophage activation.
EA036814B9 (en) 2011-11-28 2021-12-27 Мерк Патент Гмбх Anti-pd-l1 antibody (embodiments), composition comprising this antibody and use thereof
MX356337B (en) 2011-12-15 2018-05-23 Hoffmann La Roche Antibodies against human csf-1r and uses thereof.
KR20140127855A (en) 2012-02-06 2014-11-04 제넨테크, 인크. Compositions and methods for using csf1r inhibitors
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
EP3539984A1 (en) 2012-05-11 2019-09-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG11201502827RA (en) 2012-11-09 2015-05-28 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
AR095882A1 (en) 2013-04-22 2015-11-18 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST
AR097584A1 (en) 2013-09-12 2016-03-23 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1

Also Published As

Publication number Publication date
TW201444873A (en) 2014-12-01
JP2016516798A (en) 2016-06-09
US20160220669A1 (en) 2016-08-04
AR095882A1 (en) 2015-11-18
MX2015014500A (en) 2016-02-22
CN104995213A (en) 2015-10-21
CA2898591A1 (en) 2014-10-30
EP2989125B1 (en) 2019-09-11
JP6506254B2 (en) 2019-04-24
EP2989125A1 (en) 2016-03-02
HK1211305A1 (en) 2016-05-20
KR20150132580A (en) 2015-11-25
WO2014173814A1 (en) 2014-10-30
RU2015149929A (en) 2017-05-25
US20140314771A1 (en) 2014-10-23
US9192667B2 (en) 2015-11-24

Similar Documents

Publication Publication Date Title
BR112015020911A2 (en) antibody, use of a combination and treatment method
CY1120398T1 (en) HUMANITIZED ALPHA-SYNOCLINE ANTIBODIES
PH12016500482A1 (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
CR20190350A (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFß1 INHIBITORS AND USE THEREOF
MY191169A (en) Anti-fcrh5 antibodies
MX2016003129A (en) Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1.
BR112016018891A2 (en) anti-dll3 antibodies and drug conjugates for use in melanoma
DOP2016000315A (en) MONOCLONAL ANTIBODIES AGAINST THE HER2 EPITHOPE AND ITS METHODS OF USE
PH12015502788A1 (en) Antibody formulations and methods
BR112015021521A2 (en) anti-crth2 antibodies and methods for their use
EA201692477A1 (en) COMPOSITIONS AND METHODS OF APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
MX2020008436A (en) ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE.
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
BR112015030356A2 (en) methods of treatment of a taupathy
MX2016002645A (en) Combination therapy for the treatment of glioblastoma.
CR20160270A (en) ANTI-TAU ANTIBODIES (pS422) HUMANIZED AND USED METHODS
MX2015008313A (en) Combination therapy of anti-her3 and anti-her2 antibodies.
BR112015027309A2 (en) antibody, composition, method of treatment and use of an antibody
CL2015002724A1 (en) Methods to treat crohn's disease using an anti-il23 antibody
MX2019005299A (en) Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases.
AU2016282877A8 (en) Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias
CL2017000212A1 (en) Angiopoietin 4-like anti-protein antibodies and methods of use
BR112019023742A2 (en) anti-trkb antibodies
MX2019014090A (en) Methods for the treatment of chronic pouchitis.
BR112015031585A2 (en) pharmaceutical composition

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.